Full Text PA-95-083 WOMEN'S HIV RISK AND PROTECTIVE BEHAVIORS NIH GUIDE, Volume 24, Number 30, August 18, 1995 PA NUMBER: PA-95-083 P.T. 34 Keywords: AIDS Risk Factors/Analysis Behavioral/Social Studies/Service Disease Prevention+ National Institute on Drug Abuse National Institute of Mental Health PURPOSE The purpose of this program announcement (PA) is to support basic social and behavioral research on women's HIV risk and/or protective behaviors combined with community-level intervention strategies aimed at understanding and preventing HIV/AIDS in women whose drug and sex practices put them at high risk of HIV infection, i.e., not-in- treatment injection drug users (IDUs), crack users, injecting and noninjecting sexual partners of male and/or female IDUs, and women who trade sex for drugs, money, or subsistence. Historically, these women have been omitted from research or have been difficult to reach and retain in research; as a result, the knowledge base is often limited to the male experience. Because of the increasing and disproportionate numbers of women acquiring HIV disease, this PA seeks to widen the research base on HIV risk behaviors and risk- taking contexts by focusing on women and including protective behaviors and contexts in addition to risks. The NIH Office of AIDS Research has approved monies to support research in several areas related to this announcement, including HIV in women and children and behavioral research in drug-abusing populations. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. This PA, Women's HIV Risk and Protective Behaviors, is related to the priority areas of alcohol and other drugs and mental health and mental disorders. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-00474-0 or Summary Report: Stock No. 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325 (telephone 202-512-1800). ELIGIBILITY REQUIREMENTS Applications may be submitted by foreign and domestic, for-profit and non-profit organizations, public and private, such as universities, colleges, hospitals, laboratories, units of State and local governments, and eligible agencies of the Federal Government. Racial/ethnic minority individuals, women, and persons with disabilities are encouraged to apply as principal investigators. MECHANISM OF SUPPORT Awards made under this PA will use the investigator-initiated research project grant (R01) mechanism. Because the type and scope of proposed research responsive to this PA may vary, it is anticipated that the size and period of the award will vary also. RESEARCH OBJECTIVES Background By year end 1994, more than 58,000 U.S. women were reported with AIDS. In 1994, 41 percent of these cases resulted from injection drug use, and 15 percent resulted from heterosexual contact with an IDU (Centers for Disease Control (CDC) 1995). Indeed, women's drug- and sex-risks for HIV frequently co-occur. Women's drug use often involves membership in a network with HIV-infected individuals where direct and indirect sharing of injection equipment and/or sexual liaisons are transacted and where the social context (e.g., shooting gallery) affects the likelihood of transmitting HIV. Women's drug use may also lead to trading sex for drugs or money, especially when they smoke crack cocaine. Studies show that drug-dependent women are more likely than men to engage in high-risk sex and that women IDUs are more likely to acquire HIV sexually than men. Violence may be an additional risk factor, because women with abusive partners practice more HIV risk behaviors and are less likely to seek drug treatment, otherwise reduce risky behavior, or disclose their HIV status to their partners than nonabused women. Data on women's drug use and HIV serostatus are available from National Institute on Drug Abuse's (NIDA) Cooperative Agreement Research Program, which tested 2,975 women for HIV between July 1, 1992 and December 31, 1993. Of these, 10.6 percent were seropositive. By drug use category of the last 30 days, seropositivity occurred in 8.5 percent of women who injected drugs, in 13.4 percent of women who injected drugs and used crack cocaine, and in 9.9 percent of women who used crack but did not inject. While the last category -- crack only -- does not consider injection history, a connection between crack use and sexual transmission is emerging. A recent three-city study of young adults in the inner city found that crack smokers had significantly higher rates of HIV seropositivity (15.7 percent) than nonsmokers (5.2 percent), and seroprevalence was highest among women (Edlin et al., 1994). In addition, CDC data indicate that the fastest growing exposure categories of AIDS involve heterosexual contact. Heterosexual contact cases in women increased by 108 percent between 1989 and 1992, compared with increases of 43 percent among IDUs and 21 percent in homosexual/bisexual men (Haverkos, 1993). Women's unique HIV transmission contexts and behaviors, including the link between drug dependence and risky sex as well as the potential for vertical transmission to infants, have implications for the development of targeted, gender-specific risk reduction interventions, including programs for pregnant women. It is also important to note that HIV in this country has disproportionately affected African Americans and Hispanics. These groups constitute approximately 18 percent of the U.S. population, but 77 percent of AIDS cases in women in 1994 (rates for African American and Hispanic women were 16 and 7 times higher, respectively, than for white women). Similarly, a majority of perinatally-acquired pediatric AIDS cases were in African Americans and Hispanics (again, mothers' exposure categories were chiefly drug-related). Research Goals and Issues Given gender differences in life experiences, perceptions, social statuses, and HIV risk behaviors, there is reason to believe that HIV interventions and prevention messages must be tailored for women. The principal goals of this PA are to develop and implement gender- specific research strategies that address HIV prevention in groups of women whose behaviors and relationships place them at high risk of HIV infection. NIDA and the National Institute of Mental Health (NIMH) will support basic behavioral/social science research projects and/or evaluations of behavioral change strategies. These projects should build on and extend existing knowledge about HIV risks, prevention, and protective factors in women. For each proposed project, it is suggested that applicants review the relevant theoretical, empirical, and methodological literature; identify unresolved questions related to the determinants and contexts of drug use and HIV risk and protective behaviors in women who are not in treatment; develop and implement gender-related intervention strategies and measurement procedures; and present a plan for rigorous community-based research to address the outstanding questions. Because behavioral change is often multidimensional, it would be useful for applicants to propose measures covering a range of structural, social, and psychological factors and rely on qualitative as well as quantitative research strategies. Most importantly, applicants are encouraged to describe the unique contributions and/or integrative value of their proposed studies to understanding HIV prevention in women and to consider race/ethnicity factors in these studies. At least four themes are of interest. Basic research in field settings is needed on (1) the social and structural contexts of women's HIV risk behavior transactions and (2) determinants, mediators, and reinforcers of women's HIV risk and/or protective behaviors related to drug use, injection equipment, and sex. Community-based intervention research is needed to (3) develop gender-specific methodologies and instrumentation to recruit and retain women in research and measure their behaviors, and (4) develop and evaluate behavior change strategies aimed specifically at women. Overlap and integration of these themes are encouraged. Thematic issues can include but are not limited to: 1. The Social and Structural Contexts of Women's HIV-Related Behaviors and Transactions. Studies are encouraged that focus on social structures and social contexts of women's HIV-related behavior transactions as well as barriers and opportunities for change. Suggested themes include: o Gender-specific interpersonal contexts of HIV risk behaviors. Issues include gender-specific barriers in relationships (e.g., power differentials) with violent or nonviolent sexual partners and/or drug partners that affect women's HIV risk behaviors and the ability to decrease their risks. o Gender-specific economic contexts of HIV risks and barriers to change. Issues include trading sex for drugs, money, or subsistence, as well as economic pressure on sex trade workers to have unsafe sex. The economic context of living "on the streets" by runaway and homeless young women may also affect their risk of infection via drug or sex practices. o Structural contexts affecting access to prevention aids and behavior change. Macro contexts include community policy/programs affecting access to needles and condoms and/or law enforcement practices against drug use, sex trade, or illegal immigration, which may lead women to avoid contact with HIV prevention programs for fear of being identified, prosecuted, and/or losing custody of their children. Also important are medical care and drug abuse services system factors that may influence the delivery and effectiveness of HIV interventions (e.g., linkage of primary medical care, HIV prevention, drug abuse treatment, and treatment of comorbid mental disorders). o Membership/roles in social networks. Using qualitative and quantitative approaches to map linkages between individuals, issues involve nonrandom properties of networks, norms, and group dynamics that socially isolate and/or affect behavioral transactions across cultural, age, and gender groups. Suggested themes include: o Composition and stability of drug and sex networks o Nonrandom injection sequencing within networks of IDUs o Gender roles and the organization of drug procurement o Lesbian/gay IDU networks and bridges to other networks o Norms about needle hygiene and exchange of sex for drugs o Gangs/cliques/street youth and the initiation and extension of sexual activity and drug use 2. Determinants, Mediators, and Reinforcers of Women's HIV-Related Behaviors. NIDA and NIMH are interested in behavioral influences especially as they vary demographically and/or culturally. Suggested themes are: o Physical, sexual, and/or emotional abuse. Research is needed to address physical and/or sexual violence against women and the relationship of violence and abuse to high- risk behaviors and women's ability to adopt HIV risk- reduction practices. Young women in abusive home settings may be a critical group. o The effect of serostatus on women's HIV risk behaviors and behavior change. Issues include the role of HIV antibody testing and/or serostatus on behavior, motivation to change, and prevention efforts; also how fertility/motherhood issues interact with serostatus to affect behavior change. o The effect of pregnancy, childbearing, and childrearing on women's HIV risk behaviors and behavior change. Research is needed on whether these conditions affect the social isolation of women and their access/receptivity to HIV risk-reduction measures. o Women's reasoning/relational styles. Issues include women's unique psychosocial development and gender socialization and the resulting effect on the ability to implement risk reduction or interpret prevention messages. 3. Gender-Specific Methodological and Measurement Studies. NIDA and NIMH encourage the development of methodologies and measures sensitive to women, especially multidimensional outcome measures of behavior change. Suggested themes include: o Innovative strategies, sampling, and tracking plans to identify, access, recruit, engage, intervene with, retain, and follow up women at highest risk for HIV. These women, particularly when in abusive relationships, are often hard to reach, tend to drop out, and are lost to followup. o Development of instruments and scales with proven validity and reliability among women. Design specificity to different racial/ethnic populations is especially desired. o New techniques or technologies for accruing data efficiently and economically. Investigators are encouraged to develop innovative strategies to deliver research findings to the field in a timely fashion. 4. Gender-Specific Behavior Change Interventions. NIDA and NIMH wish to support theoretically based interventions as well as interventions based on what is learned in basic research: o Studies are needed to evaluate what works, for whom it works, under what circumstances it works, and how long it works, taking into account the levels of risk engaged in as well as the episodic nature of HIV risk behaviors/behavior change and need for intermittent reinforcement. o Prevention messages. Studies are sought that address how women's behavior change is related to the structure, context, duration, and content of education and prevention messages, specifically, which media and messages have the most impact or cumulative impact (e.g., news reports, talk shows, movies, personal experiences, community messages in churches, clinics, or social agencies). o Studies of strategies to link HIV behavior change interventions for women to health care services and to drug abuse treatment, and vice versa (i.e., linkage of health care and drug treatment services to HIV behavior change interventions). o Woman-controlled technologies, such as the female condom or microbicides. Issues include whether these technologies are viable options for women at high risk of HIV; perceptions surrounding the technologies; reasons for and barriers facing their use; and optimal approaches to educate women (and men). o Other studies are encouraged that focus on individual gender- related attributes and/or the interaction of gender with race/ethnicity and the impact of these attributes and statuses on HIV risk behaviors and behavior change. NIDA Policy on HIV Counseling and Testing Researchers funded by NIDA, who are conducting research in community outreach settings, clinics, hospital settings, or clinical laboratories, and have ongoing contact with clients at risk for HIV infection, are strongly encouraged to provide HIV risk-reduction education and counseling. HIV counseling should include offering HIV testing available on-site or by referral to other HIV testing services. Persons at risk for HIV infection include injection drug users, crack cocaine users, and sexually active drug users and their sexual partners. Health Services Research Priorities Historically, NIDA's research agenda has included a health services research component; more recently, NIDA has placed increased importance on health services research, especially related to cost and financing as well as organizational aspects of drug abuse treatment/prevention. Therefore, applicants are encouraged to address one or more issues on: costs, cost effectiveness, access and utilization of services, financing, characteristics and matching, and organization and management. Only 25 percent of the NIDA grant budget may be used for services. These services must be directly related to the research study. Therefore, applicants who choose to address health services issues are strongly encouraged to form linkages and agreements with community service agencies. INCLUSION OF WOMEN AND MINORITIES IN RESEARCH INVOLVING HUMAN SUBJECTS It is the policy of the NIH that women and members of minority groups and their subpopulations must be included in all NIH supported biomedical and behavioral research projects involving human subjects, unless a clear and compelling rationale and justification is provided that inclusion is inappropriate with respect to the health of the subjects or the purpose of the research. This new policy results from the NIH Revitalization Act of 1993 (Section 492B of Public Law 103-43) and supersedes and strengthens the previous policies (Concerning the Inclusion of Women in Study Populations, and Concerning the Inclusion of Minorities in Study Populations), which have been in effect since 1990. The new policy contains some provisions that are substantially different from the 1990 policies. All investigators proposing research involving human subjects should read the "NIH Guidelines For Inclusion of Women and Minorities as Subjects in Clinical Research," which have been published in the Federal Register of March 28, 1994 (FR 59 14508-14513) and reprinted in the NIH Guide for Grants and Contracts, Volume 23, Number 11, March 18, 1994. Investigators may also obtain copies of the policy from the program staff listed under INQUIRIES. Program staff may also provide additional relevant information concerning this policy. Confidentiality. The Public Health Service (PHS) has a formal policy concerning Certificates of Confidentiality and communicable disease reporting. In brief, the policy reflects the expectation that research projects will cooperate with State and local health departments to assure that the purposes of reporting are accomplished, and the expectation that health departments will develop relationships with research projects that assist their mission without thwarting the research goals. A description of the policy as well as Instructions for Applicants can be obtained after award. APPLICATION PROCEDURES Applications are to be submitted on the grant application form PHS 398 (rev. 5/95) and will be accepted at the standard AIDS receipt dates indicated in the application kit. Application kits are available at most institutional offices of sponsored research and may be obtained from the Office of Grants Information, Division of Research Grants, National Institutes of Health, 6701 Rockledge Drive, Room 3032 - MSC 7762, Bethesda, MD 20892-7762, telephone 301-710-0267. The title and number of this PA must be typed in Item 2 on the face page of the application. The completed original and five legible copies must be sent or delivered to: Division of Research Grants National Institutes of Health 6701 Rockledge Drive, Room 1040 - MSC-7710 Bethesda, MD 20892-7710 Bethesda, MD 20817 (for courier/overnight service) REVIEW CONSIDERATIONS Applications that are complete will be evaluated for scientific and technical merit by an appropriate peer review group convened in accordance with standard NIH peer review procedures. As part of the initial merit review, all applications will receive a written critique and undergo a process in which only those applications deemed to have the highest scientific merit, generally the top half of the applications under review, will be discussed, assigned a priority score, and receive a second level review by the appropriate national advisory council or board. Review Criteria o scientific or technical significance and originality of the proposed research; o appropriateness and adequacy of the research approach and methodology proposed to carry out the research; o qualifications and research experience of the principal investigator and staff; o availability of resources necessary to the research; o appropriateness of the proposed budget and duration in relation to the proposed research; and o adequacy of plans to include both genders and minorities and their subgroups as appropriate for the scientific goals of the research. Plans for the recruitment and retention of subjects will also be evaluated. The initial review group will also examine the provisions for the protection of human and animal subjects, and safety of the research environment. AWARD CRITERIA Applications will compete for available funds with all other approved applications. The following will be considered in making funding decisions: quality of the proposed project as determined by peer review, availability of funds, and program priority. INQUIRIES Inquiries are encouraged. The opportunity to clarify any issues or questions from potential applicants is welcome. Direct inquiries regarding programmatic issues to: Susan Coyle, Ph.D. Division of Epidemiology and Prevention Research National Institute on Drug Abuse 5600 Fishers Lane, Room 9A-42 Rockville, MD 20857 Telephone: (301) 443-6720 FAX: (301) 443-2636 Email: [email protected] Willo Pequegnat, Ph.D. Office on AIDS National Institute of Mental Health 5600 Fishers Lane, Room 10-75 Rockville, MD 20857 Telephone: (301) 443-6100 FAX: (301) 443-9719 Email: [email protected] Direct inquiries regarding fiscal matters to: Gary Fleming, J.D., M.A. Grants Management Branch National Institute on Drug Abuse 5600 Fishers Lane, Room 8-A-54 Rockville, MD 20857 Telephone: (301) 443-6710 FAX: (301) 594-6847 Email: [email protected] Diana S. Trunnell Assistant Chief Grants Management Branch National Institute of Mental Health 5600 Fishers Lane, Room 7C-08 Rockville, MD 20857 Telephone: (301) 443-3065 FAX: (301) 443-6885 Email: [email protected] AUTHORITY AND REGULATIONS This program is described in the Catalog of Federal Domestic Assistance No. 93.279 and 93.242. Awards are authorized under the Public Health Service Act, Section 301 and administered under PHS grants policies and Federal Regulations 42 CFR 52 and 45 CFR Part 74. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency Review. Grants will be administered under PHS grants policy as stated in the Public Health Service Grants Policy Statement (DHHS Publication No. (OASH) 82-50-000 GPO 0017-020-0090-1 (rev. 4/94). The PHS strongly encourages all grant recipients to provide a smoke- free workplace and promote the non-use of all tobacco products. In addition, Public Law 103-227, the Pro-Children Act of 1994, prohibits smoking in certain facilities (or in some cases, any portion of a facility) in which regular or routine education,library, day care, health care of early childhood development services are provided to children. This is consistent with the PHS mission to protect and advance the physical and mental health of the American people. .
Return to NIH Guide Main Index
Office of Extramural Research (OER) |
National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892 |
Department of Health and Human Services (HHS) |
||||||||